Prostate cancer, the second most frequent malignancy among men worldwide, can be treated using various antagonists of the androgen receptor, but many patients develop resistance within 18-24 months, ...

The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...